News | November 12, 2021
Solara Active Pharma Sciences PAT slides to Rs 29.71 cr in Q2FY22
Solara Active Pharma Sciences has reported consolidated financial results for the period ended September 30, 2021.
Solara Active Pharma Sciences has reported consolidated financial results for the period ended September 30, 2021.
The centre has an initial capacity of 500 FTEs
Covaxin is the only Covid-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the Delta variant at 65.2%
The Board of Directors of Alembic Pharmaceuticals have approved the unaudited consolidated financial results of the company for the period ended September 30, 2021.
Metropolis Healthcare has reported consolidated financial results for the period ended September 30, 2021
The Board of Directors of AstraZeneca Pharma India have approved the unaudited consolidated financial results of the company for the period ended September 30, 2021
Marksans Pharma has reported consolidated financial results for the period ended September 30, 2021
Strides Pharma Science has reported consolidated financial results for the period ended September 30, 2021
Thermo Fisher Scientific expands diagnostics portfolio to support full qPCR assay development and testing workflow
The Board of Directors of Wockhardt have approved the unaudited consolidated financial results for the period ended September 30, 2021.
Subscribe To Our Newsletter & Stay Updated
